Nanatinostat + Valganciclovir (Nana-val)
Relapsed/Refractory EBV-positive Lymphomas (including PTCL, CTCL, DLBCL)
Key Facts
About Viracta Therapeutics
Viracta Therapeutics is pioneering a precision oncology approach to treat virus-associated cancers, with a primary focus on Epstein-Barr virus (EBV)-positive malignancies. The company's proprietary platform combines a viral activator with targeted anticancer agents to selectively induce viral lytic activation in cancer cells. Its lead candidate, nanatinostat in combination with valganciclovir, is in late-stage development for EBV-positive lymphomas and nasopharyngeal carcinoma. Viracta aims to address significant unmet medical needs in oncology through its novel mechanism of action.
View full company profileAbout Viracta Therapeutics
Viracta Therapeutics is pioneering a precision oncology approach to treat virus-associated cancers, with a primary focus on Epstein-Barr virus (EBV)-positive malignancies. The company's proprietary platform combines a viral activator with targeted anticancer agents to selectively induce viral lytic activation in cancer cells. Its lead candidate, nanatinostat in combination with valganciclovir, is in late-stage development for EBV-positive lymphomas and nasopharyngeal carcinoma. Viracta aims to address significant unmet medical needs in oncology through its novel mechanism of action.
View full company profileAbout Viracta Therapeutics
Viracta Therapeutics is pioneering a precision oncology approach to treat virus-associated cancers, with a primary focus on Epstein-Barr virus (EBV)-positive malignancies. The company's proprietary platform combines a viral activator with targeted anticancer agents to selectively induce viral lytic activation in cancer cells. Its lead candidate, nanatinostat in combination with valganciclovir, is in late-stage development for EBV-positive lymphomas and nasopharyngeal carcinoma. Viracta aims to address significant unmet medical needs in oncology through its novel mechanism of action.
View full company profileAbout Viracta Therapeutics
Viracta Therapeutics is pioneering a precision oncology approach to treat virus-associated cancers, with a primary focus on Epstein-Barr virus (EBV)-positive malignancies. The company's proprietary platform combines a viral activator with targeted anticancer agents to selectively induce viral lytic activation in cancer cells. Its lead candidate, nanatinostat in combination with valganciclovir, is in late-stage development for EBV-positive lymphomas and nasopharyngeal carcinoma. Viracta aims to address significant unmet medical needs in oncology through its novel mechanism of action.
View full company profile